171 related articles for article (PubMed ID: 26985923)
1. Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
Song J; Tao ZH; Liu XY; Gong S; Gan L
Genet Mol Res; 2016 Feb; 15(1):15017866. PubMed ID: 26985923
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
3. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.
dos Santos A; Ribeiro ML; Mesquita JC; Carvalho-Salles AB; Hackel C
Prostate Cancer Prostatic Dis; 2002; 5(1):28-31. PubMed ID: 15195127
[TBL] [Abstract][Full Text] [Related]
4. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
5. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
7. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.
Sivoňová MK; Dobrota D; Dušenka R; Waczulíková I; Slezák P; Matáková T; Mahmoodová S; Mištuna D; Kliment J
Mol Biol Rep; 2012 Aug; 39(8):7871-80. PubMed ID: 22528335
[TBL] [Abstract][Full Text] [Related]
9. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
Antognelli C; Mearini L; Talesa VN; Giannantoni A; Mearini E
Prostate; 2005 May; 63(3):240-51. PubMed ID: 15538743
[TBL] [Abstract][Full Text] [Related]
10. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
11. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Tigli H; Yazici H; Dalay N
Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
[TBL] [Abstract][Full Text] [Related]
12. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
14. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
[TBL] [Abstract][Full Text] [Related]
15. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].
Guli MR; Wang JQ; Zhang JX; Deng G
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Ersekerci E; Sofikerim M; Taheri S; Demirtas A; Halis F
Genet Mol Res; 2015 Jul; 14(3):7326-34. PubMed ID: 26214411
[TBL] [Abstract][Full Text] [Related]
17. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer associated with CYP17 genotype.
Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
[TBL] [Abstract][Full Text] [Related]
20. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):120-6. PubMed ID: 12582021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]